Immune Response and Vaccine Strategies against SARS-CoV-2
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 5023
Special Issue Editors
Interests: influenza A viruses; human coronaviruses; flaviviruses; vaccines; antivirals; immune evasion; animal models; viral pathogenesis
Special Issue Information
Dear Colleagues,
The COVID-19 pandemic made us realize the importance of vaccines in protecting humans from unprecedented carnage caused by novel pathogens, especially fast-spreading respiratory viruses. We were fortunate to develop initial vaccine candidates against SARS-CoV-2 in an astonishingly short time. However, the virus has posed a formidable challenge through its constant antigenic drift and shift to evade vaccine-mediated and natural immunity. The durability of vaccine response has been another challenge, as the antibody responses against SARS-CoV-2 have been particularly short-lived. To develop better vaccines, it is crucial to understand the immune response against SARS-CoV-2, the immune correlates of protection, the determinants of the longevity of the immune response, and viral strategies to evade host immunity. In this proposed Special Issue, we will be inviting research articles and reviews from scientists across the globe specializing in this subject.
Dr. Shashank Tripathi
Dr. Kesavardana Sannula
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- SARS-CoV-2
- vaccines
- immune response
- immune evasion
- immune suppression
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.